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Abstract Purpose: Chronic pul-
monary hypertension (PH) therapy is
poorly investigated in intensive care.
Our aim was to evaluate haemody-
namic and neuroendocrine effects of
the dual endothelin-1 (ET-1) blocker
tezosentan in monocrotaline (MCT)-
induced PH. Methods: Male Wistar
rats (180–200 g, n = 194) randomly
received 60 mg kg-1 MCT or vehi-
cle, subcutaneously, and 2 days later,
a subgroup of MCT-injected rats was
gavaged with 300 mg kg-1 day-1
bosentan (MCT BOS, n = 46), while
another (MCT, n = 125) and control
rats (Ctrl, n = 23) received vehicle.
At 25–30 days, 48 h after interrupting
bosentan, rats randomly underwent
either a dose–response evaluation
(0.5–20 mg kg-1, n = 7 each group)
or a 4 h perfusion of tezosentan
(20 mg kg-1 in 10 min ? 10 mg g-1
h-1) or vehicle (n = 8 per group,
each). Haemodynamics, including
blood gas analysis, were evaluated
after thoracotomy under anaesthesia.
After plasma, right ventricle (RV)
and lung collection, plasma ET-1,
cytokines, nitrate and 6-keto-PGF1a,
and lung and right ventricular gene
expression and cyclooxygenase
(COX) and nitric oxide synthase
(NOS) activities were quantified.
Results: Monocrotaline resulted in
PH, RV dilation and decreased car-
diac output (CO) that were attenuated
in MCT BOS. Pulmonary hyperten-
sion was attenuated by tezosentan
without systemic hypotension.
Tezosentan increased CO without
changing ventilation-perfusion
matching. Both bosentan and tezos-
entan reduced ET-1 and cytokine
plasma levels and tissue expression,
and inducible NOS and COX-2 RV
activities. Bosentan increased nitrate
plasma levels and non inducible NOS
activities whereas tezosentan
decreased circulating 6-keto-PGF1a
but increased lung COX-1 activity.
Conclusions: Tezosentan may be
useful for haemodynamic handling
and bosentan replacement in critically
ill PH patients exerting important
beneficial neuroendocrine and anti-
inflammatory actions.
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Introduction
Pulmonary hypertension (PH), the most serious chronic
disease of the pulmonary circulation, defined by mean
pulmonary artery pressure greater than 25 mmHg, con-
sists of an heterogeneous group of disorders characterized
by vascular remodelling that leads to right ventricular
(RV) failure. Currently, combined lung arteries vasodi-
lators are the mainstay of treatment [1, 2]. Regrettably,
acute therapy, which is of major importance to critical
care practice, has been poorly investigated [3]. One of the
most successful therapeutic approaches to PH, endothelin-
1 (ET-1) blockade [4], is mostly restricted to chronic oral
administration, and therefore is of limited utility. Tezos-
entan, a dual ET-1 antagonist, however, was developed
for intravenous use and optimized to be rapidly-acting and
short-lived, [5] and therefore is suited for fine dose
adjustment to a desired haemodynamic effect. Moreover,
it has advantages over the cumbersome inhaled therapies.
Nevertheless, most lung vessel vasodilators are negative
inotropes, either by direct myocardial actions, systemic
hypotension, decreased coronary perfusion [6] or simply
by reducing afterload [7]. Additionally, disturbances in
ventilation-perfusion (VQ) matching are also usual, and
could lead to hypoxia [8]. Endothelin-1 is a strong posi-
tive inotrope [9] but when chronically activated, as it
happens in the failing heart, this supportive role is lost
[10], suggesting ET-1 blockade could actually improve
performance. As for VQ matching, acute ET-1 antago-
nism improved alveolar-arterial O2 difference in lung
injury [11] and did not disturb VQ matching in pulmonary
thromboembolism [12]. Tezosentan has been found ben-
eficial in acute experimental PH [13, 14] and also in an
experimental model of left–right shunt in the newborn
lamb [15], but a characterization of its pulmonary and
myocardial effects in adult experimental chronic PH is
lacking. Additionally, the myocardial and pulmonary
vascular mechanisms involved in ET-1 blockade and
whether tezosentan can be an effective replacement
therapy for bosentan is also undefined. Our goal was to
evaluate the haemodynamic, local myocardial and pul-
monary, and systemic neuroendocrine effects of acute
ET-1 antagonism with tezosentan in chronic PH induced
by monocrotaline (MCT) in rats and to assess whether
these were altered by previous chronic therapy with
bosentan.
Methods
Animal model
Male Wistar rats, 180–200 g (Charles-River, Barcelona,
Spain), randomly received 60 mg kg-1 MCT (Sigma
Chemical, St Louis, MO) or vehicle subcutaneously
administered. Randomly, 48 h later, some MCT-injected
animals were gavaged 300 mg kg-1 day-1 bosentan
(30 mg mL-1 in 5% gum Arabic; kindly provided by
Actelion pharmaceuticals) (MCT BOS; n = 46), while
others (MCT; n = 125) and controls (Ctrl; n = 23)
received vehicle. Rats were housed five per cage under
controlled environment (22C, 12:12 h light–dark).
Experiments conformed to the Guide for Care and Use
of Laboratory Animals (National Institutes of Health,
Pub.No. 85-23, revised 1996).
Haemodynamics
After bosentan or vehicle interruption for 48 h, at days
25–30, rats were anaesthetized with sevoflurane (2.5–3%
for maintenance) and 150 lg kg-1 intraperitoneal fenta-
nyl, endotracheally intubated, mechanically ventilated
(150 min-1, 100% O2, 14–16 cmH2O inspiratory pres-
sure, with tidal volume adjusted to animal weight, and
4 cmH2O end-expiratory pressure; TOPO Small Animal
Ventilator, Kent Scientific Inc.) and kept at 38C on a heating
pad. Warm Ringer’s solution (30 mL kg-1 h-1) was
perfused through the femoral vein (Multi-Phaser
TM
, NE-
1000, New Era Pump Systems). After left thoracotomy,
under surgical microdissection (Wilde M651, Leica mi-
crosystems), pressure–volume (PV) catheters were
implanted through the apex along the left ventricle (LV)
and RV (SPR-838 and PVR-1045, Millar Instruments,
Houston, TX, respectively) long axes, a transit-time flow-
probe was placed in the ascending aorta (200–367, Triton
Technology), and a silk thread was passed around the
inferior vena cava (IVC). Arterial blood gas (ABG)
samples were collected (Stat Profile pHOx, Nova
Biomedical) from the femoral artery and ventilation
was adjusted to achieve normocapnia. After a 15 min
stabilization, recordings were done under constant hae-
modynamics and during transient IVC occlusion at
sustained end-expiration. Parallel conductance and field
inhomogeneity were estimated by 50 lL 10% saline
injections and cardiac output (CO) measurement (Active
Redirection Transit Time Flowmeter, System 6, Triton
Technology), respectively. Data were continuously
acquired (MPVS 300, Millar Instruments), digitally
recorded at 1000 Hz (ML880 PowerLab 16/30, Millar
Instruments), and analyzed (PVAN 3.5
TM
, Millar
Instruments). First, we performed a dose–response hae-
modynamic evaluation (n = 7 each group) of 0.5, 1, 5,
10, and 20 mg kg-1 intravenous tezosentan doses (kindly
provided by Actelion pharmaceuticals; freshly dissolved
in saline). Based on this assessment, an additional set of
rats randomly received either an intravenously adminis-
tered 20 mg kg-1 dose followed by 10 mg kg-1 h-1
tezosentan perfusion (TEZO; n = 8 per group), or saline
(Vehicle; n = 8 per group). Haemodynamic recordings
and ABG collection were repeated 1 h after stable effect.
1051
A 2 mL venous sample was withdrawn, centrifuged and
stored (-20C) after 4 h. Animals were then euthanized
by exsanguination under anaesthesia. Heparinised blood
was used for volume calibration using a cuvette with
standard wells. The heart, the RV, the LV and interven-
tricular septum (IVS), and the lungs were weighed, snap
frozen in liquid nitrogen and stored at -80C. A flow-
chart with experimental methods can be found in
Supplemental Fig. 5.
Gene expression
Total mRNA extracted from lung and RV free-wall
underwent two-step real-time reverse transcription-poly-
merase chain reaction as described [16]. Results,
normalized for b-actin, are presented relative to Ctrl
Vehicle. Primers are given in Supplemental Table 1.
Enzymatic activity
Cyclooxygenase (COX) and nitric oxide synthase (NOS)
activities (760151 and 760871, Cayman Chemical Com-
pany, respectively) were quantified in homogenates of
equal amounts of each sample with and without specific
COX-2, DuP-697 (70645, Cayman Chemical Company),
and inducible NOS (iNOS), aminoguanidine (396494,
Sigma-Aldrich), inhibitors. Background activity was
assessed by heat-inactivation. Preliminary ultrafiltration
was carried out in the NOS assay to concentrate proteins
and eliminate tissue nitrates (Amicon Ultra 30K,
Millipore).
Plasma mediators
Circulating ET-1 (S-1171, Peninsula laboratories), inter-
leukin-6 (IL-6; DE4845, Demeditec diagnostics GmbH)
and tumor necrosis factor-a (TNF-a; 45-TNFRTU-E01,
Alpco Diagnostics
TM
) were quantified by quantitative
enzyme immunoassay (UVM-340 monochromator based
reader, ASYS Hitech GmbH). For ET-1 extraction was
performed with Sep-Pak C18 columns (Waters). Nitrates
and 6-keto-PGF1a, stable nitric oxide (NO) and prosta-
cyclin (PGI2) metabolites, respectively, were also
quantified (Cat. No. 760871 and Cat. No. 515211, Cayman
Chemical Company, respectively) after removal of large
molecular weight proteins by ultrafiltration (Amicon
Ultra 30K, Millipore).
Statistical analysis
Analysis by two-way repeated-measures ANOVA for
dose–response, two-way ANOVA for haemodynamics,
ABG, gene expression, neuroendocrine and enzyme
activities, and paired t test for perfusion, with Holm-
Sidak’s method for post hoc comparisons. ANOVA on
ranks was used for non-normally distributed data. Chi-
square was used to compare mortality. Two-tailed
P \ 0.05. Variables: mean ± SEM.
Results
Animal model
Mortality rates up to the point of haemodynamic evalu-
ation were 77 and 43% (P \ 0.001), in MCT and MCT
BOS, respectively, and six and three additional rats were
lost during haemodynamic evaluation. None of Ctrl ani-
mals died during follow-up or haemodynamic evaluation.
Monocrotaline and MCT BOS presented lower body
weights. MCT showed increased RV weight and RV to
LV ? IVS weight ratio which was attenuated in MCT
BOS. No differences were observed between TEZO and
Vehicle (Supplemental Table 2).
Dose–response evaluation
Monocrotaline and MCT BOS showed increased RV
maximal pressures that were dose-dependently reduced
by TEZO, while no effect was observed in Ctrl. Dis-
tinctly, TEZO only reduced LV pressure in Ctrl, not in
MCT or MCT BOS. MCT however had lower LV max-
imal pressures compared with both Ctrl and MCT BOS
(Supplemental Fig. 6). Higher doses elicited no additional
effects (not shown).
Haemodynamic effects of tezosentan
Baseline and IVC occlusion derived haemodynamic
parameters are given in Tables 1 and 2, respectively
(representative PV loops presented in Supplemental
Fig. 7). Compared with Ctrl, MCT showed not only PH
and RV afterload (Table 1), as assessed by maximal RV
pressure and arterial elastance (EA), respectively, but also
lower heart rate (HR), decreased CO (Fig. 1a), compro-
mised RV ejection fraction (EF), disturbed relaxation, as
assessed by s (Table 1), and diastolic dysfunction, evi-
denced by an upward shift of the end-diastolic PV
relationship (Table 2). Monocrotaline BOS showed an
overall improvement compared with vehicle-treated
MCT. Acute tezosentan perfusion also decreased maximal
RV pressure and Ea both in MCT and MCT BOS, com-
pared with vehicle perfusion, whereas CO (Fig. 1a), EF,
s and end-diastolic PV relationships were only improved
in MCT and not in MCT BOS. The slope of end-systolic
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PV relationship and preload recruitable stroke work
(PRSW), load-independent indexes of contractility, were
increased in MCT compared with Ctrl, and were neither
attenuated by bosentan nor tezosentan. Since end-systolic
PV relationship slope was preserved in both MCT BOS
and MCT TEZO while EA decreased compared with
MCT, ventriculo-vascular coupling improved (Fig. 1b).
As for the LV, MCT showed reduced maximal pressures,
reduced end-diastolic volume and EF along with pro-
longed s (Table 1) compared with Ctrl, while MCT BOS
did not. Tezosentan perfusion also increased LV end-
diastolic volumes and EF in MCT whereas in Ctrl it
decreased maximal pressure. MCT showed upward-shif-
ted LV end-diastolic PV relationships that were restored
to normal both by chronic bosentan and by acute tezos-
entan therapy while PRSW was unchanged both in MCT
compared with Ctrl or by chronic and acute ET-1
blockade (Table 2).
Respiratory effects of tezosentan
Animals were normoventilated and maintained acid–base
balance throughout perfusion. Arterial O2 pressure under
stable ventilation was used as surrogate of oxygenation.
Both MCT and MCT BOS showed decreased arterial O2
pressures that were not altered by TEZO (Supplemental
Table 3).
Effects of tezosentan on endothelin-1 and cytokine
production
Monocrotaline showed increased plasma levels of ET-1,
IL-6 and TNF-a (Fig. 2c), that were accompanied by
increased local expression of TNF-a and ET-1 in the RV
(Fig. 2b) and TNF-a and IL-6 in the lung (Fig. 2a). These
were partly prevented by chronic ET-1 antagonism and
Table 1 Haemodynamics before and after vehicle and tezosentan perfusion
Before After
Ctrl MCT MCT BOS Ctrl MCT MCT BOS
Vehicle
RV
Pmax (mmHg) 34.6 ± 1.5 56.8 ± 3.9* 43.5 ± 3.8*
 30.8 ± 1.6 55.8 ± 2.5* 43.7 ± 4.3*
EDP (mmHg) 2.6 ± 0.6 4.4 ± 0.4* 3.4 ± 1.0 3.1 ± 1.2 3.8 ± 0.4 3.2 ± 0.8
EDV (lL) 229 ± 22 279 ± 32* 239 ± 39 226 ± 23 281 ± 29 259 ± 43
EF (%) 68 ± 5 31 ± 4* 43 ± 4* 66 ± 5 30 ± 4* 45 ± 4*
s (ms) 8.88 ± 0.58 10.03 ± 0.77* 9.85 ± 0.79 9.76 ± 0.43 10.57 ± 0.60 9.65 ± 1.17
EA (mmHg lL
-1) 0.24 ± 0.03 0.82 ± 0.17* 0.54 ± 0.09* 0.23 ± 0.03 1.02 ± 0.05* 0.44 ± 0.07*
LV
Pmax (mmHg) 128.0 ± 2.4 98.0 ± 7.7* 122.3 ± 9.4
 122.9 ± 2.3* 98.5 ± 7.4* 121.4 ± 7.6
EDP (mmHg) 4.5 ± 0.8 5.4 ± 0.9 4.2 ± 0.6 3.7 ± 0.6 5.7 ± 1.3 6.4 ± 0.9
EDV (lL) 244 ± 28 194 ± 31* 180 ± 19 232 ± 22 191 ± 24 209 ± 32
EF (%) 62 ± 3 51 ± 11* 53 ± 5 64 ± 5 47 ± 4* 46 ± 3*
s (ms) 6.99 ± 0.22 8.90 ± 0.29* 7.86 ± 0.56 7.44 ± 0.44 8.70 ± 0.61* 8.80 ± 0.84
EA (mmHg lL
-1) 0.93 ± 0.09 1.37 ± 0.36* 1.28 ± 0.17* 0.89 ± 0.09 1.28 ± 0.22* 1.35 ± 0.20*
HR (min-1) 429 ± 15 384 ± 23* 419 ± 11 419 ± 12 372 ± 16* 399 ± 17
Tezosentan
RV
Pmax (mmHg) 33.4 ± 0.9 60.3 ± 4.2* 52.1 ± 5.4*
 28.6 ± 11.1 49.7 ± 2.5* 42.3 ± 2.6*
EDP (mmHg) 2.4 ± 0.4 4.2 ± 0.3* 3.9 ± 0.8 1.7 ± 0.4 3.1 ± 0.4 2.6 ± 0.7
EDV (lL) 239 ± 14 289 ± 11* 231 ± 30 248 ± 20 274 ± 40 256 ± 32
EF (%) 68 ± 3 32 ± 3* 48 ± 3* 63 ± 4 48 ± 4* 45 ± 3*
s (ms) 8.85 ± 0.47 11.32 ± 0.44* 9.78 ± 0.99 8.57 ± 0.50 9.76 ± 0.44 9.67 ± 1.17
EA (mmHg lL
-1) 0.21 ± 0.01 0.77 ± 0.10* 0.60 ± 0.10* 0.20 ± 0.01 0.45 ± 0.05 0.40 ± 0.06
LV
Pmax (mmHg) 124.8 ± 2.6 98.7 ± 3.2* 125.7 ± 8.5
 110.9 ± 6.6 94.7 ± 3.3* 116.9 ± 7.5
EDP (mmHg) 4.0 ± 0.7 5.1 ± 0.7 5.3 ± 0.8 4.6 ± 0.5 4.2 ± 0.5 4.4 ± 0.7
EDV (lL) 247 ± 17 189 ± 9* 213 ± 22 234 ± 24 202 ± 20 230 ± 30
EF (%) 64 ± 3 49 ± 5* 52 ± 6 66 ± 4 58 ± 3 52 ± 3
s (ms) 7.38 ± 0.17 9.96 ± 0.78* 8.33 ± 0.53 7.55 ± 0.39 9.35 ± 0.56* 8.59 ± 0.59
EA (mmHg lL
-1) 0.83 ± 0.04 1.16 ± 0.15* 1.25 ± 0.10* 0.69 ± 0.06 0.83 ± 0.10 1.01 ± 0.11
HR (min-1) 409 ± 13 354 ± 13* 399 ± 23 404 ± 16 338 ± 17* 383 ± 26
Right (RV) and left ventricular (LV) haemodynamic parameters in
vehicle-injected (Ctrl), monocrotaline-injected (MCT) and mono-
crotaline-injected bosentan-treated rats (MCT BOS)
Pmax maximal or systolic pressure, EDP end-diastolic pressure,
EDV end-diastolic volume, EF ejection fraction, s time constant of
isovolumetric relaxation, EA arterial elastance, HR heart rate
* P \ 0.01 versus Ctrl and  P \ 0.05 versus MCT on two-way
ANOVA;  P \ 0.01 versus before on paired t test; n = 8 per
group
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markedly attenuated with acute antagonism in MCT BOS
and MCT TEZO, respectively. Tezosentan also reduced
plasma levels of TNF-a and IL-6 in MCT BOS, whereas it
raised ET-1 RV expression and plasma levels in Ctrl
compared with Vehicle.
Effects of tezosentan on prostaglandin and NO
production
PGI2 metabolite 6-keto-PGF1a was increased both in
MCT and MCT BOS compared with Ctrl, which was
attenuated after TEZO perfusion, compared with Vehicle
(Fig. 3c). Contrastingly, TEZO increased 6-keto-PGF1a in
Ctrl. These plasma changes were accompanied by
increased RV activities of both COX-1 and -2 and also by
increased gene expression of COX-1 in MCT, that were
attenuated by chronic and acute ET-1 antagonism in MCT
BOS and MCT TEZO, respectively. While gene expres-
sion of COX-2, contrarily, was decreased in MCT with no
changes after either BOS or TEZO (Fig. 3b). As for the
lung, no changes were observed in either the expression
or enzymatic activity of COX-2, whereas COX-1 showed
increased gene expression in MCT, that was attenuated by
either chronic or acute ET-1 antagonism, and markedly
decreased activity both in MCT and MCT BOS, which
was attenuated only by acute ET-1 antagonism in MCT
TEZO (Fig. 3a). Plasma levels of nitrates were lower in
MCT and restored to Ctrl values or higher in MCT BOS.
Tezosentan had no effect compared with Vehicle
(Fig. 4c). Plasma changes were paralleled by lower non-
inducible NOS activity in the lung (Fig. 4a) and RV
Table 2 Inferior vena cava occlusions before and after vehicle and tezosentan perfusion
Before After
Ctrl MCT MCT BOS Ctrl MCT MCT BOS
Saline
RV
EDPVR (exponential)
k1 0.006 ± 0.001 0.015 ± 0.003* 0.011 ± 0.003 0.007 ± 0.001 0.016 ± 0.004* 0.010 ± 0.003
k2 1.24 ± 0.29 0.25 ± 0.10 0.68 ± 0.21 0.92 ± 0.22 0.33 ± 0.20 0.90 ± 0.46
ESPVR (linear)
Slope (Emax), (mmHg lL
-1) 0.22 ± 0.04 0.50 ± 0.09* 0.50 ± 0.07* 0.24 ± 0.03 0.56 ± 0.12* 0.45 ± 0.09*
Intercept (lL) -74.5 ± 34.8 71.5 ± 42.1* 33.2 ± 26.1* 7.0 ± 15.5 87.0 ± 37.9* 43.3 ± 11.47*
PRSW (mmHg) 20.8 ± 2.9 27.6 ± 3.3* 29.4 ± 3.4* 17.0 ± 2.4 28.6 ± 5.0* 29.4 ± 2.7*
LV
EDPVR (exponential)
k1 0.015 ± 0.004 0.025 ± 0.005* 0.014 ± 0.003
 0.013 ± 0.003 0.036 ± 0.003* 0.011 ± 0.002
k2 0.92 ± 0.47 2.70 ± 1.02 1.07 ± 0.53 2.69 ± 1.31 1.72 ± 0.73 1.09 ± 0.48
ESPVR (linear)
Slope (mmHg lL-1) 0.97 ± 0.23 2.42 ± 0.55* 1.89 ± 0.15 1.18 ± 0.24 2.52 ± 0.62* 1.76 ± 0.10
Intercept (lL) -28.4 ± 52.2 41.4 ± 17.8 39.9 ± 4.8 -35.0 ± 21.4 14.7 ± 12.0 23.5 ± 4.5
PRSW (mmHg) 105.6 ± 22.2 126.5 ± 27.1 124.9 ± 11.7 106.8 ± 16.0 106.2 ± 7.6 144.4 ± 8.6
Tezosentan
RV
EDPVR (exponential)
k1 0.007 ± 0.002 0.015 ± 0.002* 0.013 ± 0.002 0.007 ± 0.001 0.012 ± 0.002
 0.013 ± 0.002
k2 0.84 ± 0.17 0.25 ± 0.06 0.90 ± 0.54 0.81 ± 0.20 0.60 ± 0.11
 0.40 ± 0.22
ESPVR (linear)
Slope (Emax) (mmHg lL
-1) 0.21 ± 0.04 0.50 ± 0.06* 0.60 ± 0.03* 0.22 ± 0.04 0.52 ± 0.06* 0.47 ± 0.07*
Intercept (lL) -58.2 ± 51.1 45.9 ± 20.2* 83.3 ± 17.1* -13.2 ± 20.4 24.1 ± 9.6* 76.3 ± 35.7*
PRSW (mmHg) 17.6 ± 1.8 29.5 ± 2.6* 34.4 ± 1.4* 15.0 ± 2.0 33.6 ± 3.6* 34.5 ± 3.9*
LV
EDPVR (exponential)
k1 0.012 ± 0.002 0.023 ± 0.002* 0.013 ± 0.004
 0.013 ± 0.002 0.012 ± 0.001 0.009 ± 0.003
k2 0.85 ± 0.24 0.38 ± 0.32 0.88 ± 0.37 0.67 ± 0.28 1.15 ± 0.18
 1.04 ± 0.37
ESPVR (linear)
Slope (mmHg lL-1) 1.04 ± 0.14 2.11 ± 0.50* 1.56 ± 0.28 0.94 ± 0.12 2.25 ± 0.74* 1.70 ± 0.16
Intercept (lL) -21.2 ± 33.8 3.9 ± 24.8 44.4 ± 39.2 -25.5 ± 25.3 9.6 ± 22.6 38.5 ± 12.7
PRSW (mmHg) 104.7 ± 17.8 121.3 ± 8.8 110.8 ± 17.7 130.9 ± 25.8 136.4 ± 17.5 121.3 ± 19.6
Right (RV) and left ventricular (LV) load-independent indexes
derived from inferior vena cava occlusions in vehicle-injected
(Ctrl), monocrotaline-injected (MCT) and monocrotaline-injected
bosentan-treated rats (MCT BOS)
EDPVR end-diastolic pressure–volume relationship, k1 and k2,
indexes of exponential function, ESPVR end-systolic pressure–
volume relationship, Emax maximal elastance, PRSW, slope of
preload recruitable stroke work
* P \ 0.01 versus Ctrl and  P \ 0.05 versus MCT on two-way
ANOVA;  P \ 0.01 versus before on paired t test; n = 8 per group
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(Fig. 4b) of MCT that was attenuated by chronic ET-1
antagonism in MCT BOS but only abrogated in the RV,
not in the lung, by TEZO, whilst iNOS was overactive
both in the lungs and RV of MCT. Tezosentan markedly
attenuated both lung and RV activities whereas BOS only
attenuated RV activity. As for gene expression, while in
the RV no changes were observed in either eNOS or
iNOS, in the lung eNOS was upregulated in MCT and
MCT BOS, with no change after TEZO, and iNOS was
downregulated in MCT, which was attenuated both by
short-term and chronic ET-1 antagonism.
Discussion
We demonstrate that an acute intravenous infusion of the
short acting dual ET-1 antagonist tezosentan attenuates
PH, without compromising VQ matching or systemic
pressure and even improving CO and ventriculo-vascular
coupling, while concomitantly blunting inflammatory and
vasoconstrictor mediator production in chronic experi-
mental PH induced by MCT in rats. Part of these effects
were also observed after previous therapy with bosentan.
Monocrotaline-induced PH is a well-established
model with extensive neuroendocrine and inflammatory
activation that rapidly progresses to RV failure [16]. In
MCT we observed PH and increased afterload that were
accompanied not only by RV hypertrophy but also by
disturbed ventriculo-vascular coupling, RV dilation,
decreased EF and CO, and compromised diastolic func-
tion. As for the LV, MCT showed decreased end-diastolic
volumes, compromised diastolic function and lower LV
maximal pressures, as expected by ventricular interaction
[17]. Regarding gas exchange, under normoventilation
MCT showed lower arterial O2 pressures as expected
[18]. Also as described, circulating levels of ET-1 and RV
gene expression were increased [16], which was accom-
panied by marked inflammatory activation, as assessed by
TNF-a and IL-6 gene expression and plasma concentra-
tions [19]. Pulmonary hypertension is an inflammatory
condition with endothelial dysfunction and loss of vas-
cular control mechanisms. The imbalance between
vasodilators and vasoconstrictors, namely an altered local
ratio of thromboxane A2 (TxA2) to PGI2, decreased
expression of eNOS, and increased ET-1 plays an
important role in its pathophysiology [20]. Inflammatory
activation also compromises myocardial function. As
reported, plasma NO levels and lung activity of eNOS
were reduced in MCT-induced PH [21], while PGI2 pro-
duction was increased [22], which could be due to
concomitant heart failure (HF), with platelet activation
and systemic production [23], since it is normally
decreased in human PH [24]. Nevertheless, prostanoid
lung synthesis was compromised, since COX-1 activity
was markedly reduced, as observed in hypoxic pigs that
showed decreased PGI2 to TxA2 ratio [25]. On the other
hand, in the RV of MCT, we observed high iNOS and
inducible COX-2 activation. iNOS mediates the negative
inotropic effects of cytokines, generating high NO quan-
tities that profoundly depress myocardial function [26],
while COX-2 produces high levels of prostanoids, medi-
ating TNF-a responsiveness through TxA2 production
[27], and was shown to be upregulated in the failing heart
Fig. 1 Cardiac output (a) and right ventricular (RV) ventriculo-
vascular coupling (b) before and after perfusion of saline (Vehicle)
or tezosentan (TEZO) in vehicle-injected (Ctrl), monocrotaline-
injected (MCT) and monocrotaline-injected bosentan-treated rats
(MCT BOS); Ctrl (circular symbols), MCT (triangular symbols)
and MCT BOS (quadrangular symbols) were given either a
20 mg kg-1 TEZO intravenous loading dose during 10 min,
followed by a perfusion of 10 mg kg-1 h-1 (white symbols) or
the corresponding volume of Vehicle (black symbols). Emax
maximal elastance, EA arterial elastance. *P \ 0.01 versus Ctrl,
P \ 0.05 versus MCT and P = 0.028 versus Vehicle on two-way
ANOVA; §P \ 0.001 vs before on paired t test; n = 8 per group
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[28]. Additionally, in the failing MCT RV we also
observed decreased eNOS and increased COX-1 activi-
ties. eNOS, the major NO source in the normal heart, is
reduced in HF and restoration of its activity exerts pro-
tective actions [29], whereas COX-1 is typically increased
by oxidative stress and its antagonism exerts beneficial
effects [30].
Right ventricle disturbances were attenuated in MCT
BOS and ventriculo-vascular coupling was improved, as
reported [31]. Systemic hypotension, as assessed by LV
maximal pressures, was not observed which could be not
only due to restored LV preload and reduced ventricular
interaction but also to improved myocardial function [16]
and preserved CO. Chronic ET-1 antagonism did not alter
overall VQ matching. Contrarily to earlier stages of dis-
ease [32], chronic ET-1 antagonism reduced plasma
concentration and RV expression of ET-1 in MCT,
probably due to attenuation of PH [16, 31] and not to
ET-1 antagonism itself [5]. Indeed, plasma ET-1 levels
increased in Ctrl after tezosentan. Alongside haemody-
namic benefits and reduced ET-1 activity, MCT BOS also
showed increased NO plasma levels and eNOS lung
activity, as reported for bosentan-treated PH patients [33].
Nevertheless, our main goal was to evaluate the effects
of the short-acting intravenous dual ET-1 antagonist te-
zosentan in chronic PH. Since perfusion doses were not
previously established for this model we carried out a
dose–response evaluation. Tezosentan dose-dependently
reduced RV maximal pressures up to 20 mg kg-1, doses
higher than previously described [34], without significant
reduction of LV pressure, not only in MCT but also in
MCT BOS, suggesting an additional benefit of acute ET-1
blockade even after chronic bosentan. Based on previous
works that have shown molecular changes as soon as 4 h
after drug perfusion [35], we then evaluated haemody-
namic, respiratory and neuroendocrine responses to
Fig. 2 Lung (a) and right ventricular myocardium gene expression
(b) of tumor necrosis factor-a (TNF-a), interleukin-6 (IL-6) and
endothelin-1 (ET-1) and corresponding plasma levels (c) in vehicle-
injected (Ctrl), monocrotaline-injected (MCT) and monocrotaline-
injected bosentan-treated rats (MCT BOS) undergoing either
perfusion of vehicle (black bars) or tezosentan (TEZO; white
bars); gene expression was normalized for b-actin and is presented
in an arbitrary unit (AU), set as the average of Ctrl Vehicle.
*P \ 0.05 versus Ctrl, P \ 0.05 versus MCT, and P \ 0.05
versus vehicle; n = 7 per group
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tezosentan. While vehicle had no effects, tezosentan
attenuated PH and RV afterload, both in MCT and MCT
BOS. Ventriculo-vascular coupling, EF and CO, however,
were only improved in MCT. Similar to chronic ET-1
antagonism, tezosentan did not disturb VQ matching.
Moreover, tezosentan perfusion was also able to acutely
reduce circulating levels and RV expression of ET-1 in
MCT, as observed after chronic bosentan. Both chronic
and acute dual ET-1 antagonism with bosentan and te-
zosentan, respectively, attenuated inflammation in MCT,
namely TNF-a and IL-6 circulating concentrations and
tissue expression, which could be due not only to direct
ET-1 antagonism [36], but also to the beneficial haemo-
dynamic effects and improved CO and thus better tissue
perfusion. Additionally, it should be mentioned that the
anti-inflammatory effects of ET-1 antagonism might have
been partly responsible for improved haemodynamics and
lower ET-1 activity after acute and chronic ET-1 antag-
onism, as cytokines also induce ET-1 production [37].
Indeed, we observed a marked attenuation of inflamma-
tion induced iNOS and COX-2 activation in the RV of
MCT after either acute tezosentan perfusion or chronic
bosentan therapy. The fast haemodynamic, neuroendo-
crine and anti-inflammatory effects observed with
tezosentan are not surprising, since it has been successful
in experimental septic shock and acute lung injury [11].
As additional effect, tezosentan increased COX-1 activity
in the lungs of MCT. Although ET-1 induces the
expression of COX-1 [38], we interpret this upregulation
of COX-1 activity after ET-1 blockade as a consequence
of decreased pulmonary vascular load and increased flow,
as observed in cell culture [39]. Anti-inflammatory and
COX-mediated effects have been recently described also
for levosimendan in chronic experimental PH [40].
Concerning the effects of acute ET-1 antagonism in
PH animals that had previously undergone chronic ET-1
blockade. We must stress that even though bosentan was
withdrawn for 48 h its molecular effects surely will last
longer and therefore tezosentan was not expected to exert
major actions. Still, although we found no amelioration in
CO, we did observe reduced PH, improved ventriculo-
vascular coupling and further anti-inflammatory effects,
which may support its use as a replacement drug.
To conclude, we have demonstrated in chronic
experimental MCT-induced PH, that acute ET-1 antago-
nism with tezosentan attenuates Pulmonary hypertension
and improves CO with concomitant reduction of ET-1 and
inflammatory cytokine levels, and increased vasodilator
production. Part of these beneficial effects were also
observed after previous chronic ET-1 antagonism with
Fig. 3 Lung (a) and right ventricular myocardium (b) cyclooxy-
genase gene expression and enzymatic activity and 6-keto-PGF1a
plasma concentrations (c); gene expression and enzymatic activities
of cyclooxygenase-1 (COX 1) and -2 (COX 2) and plasma
concentrations of 6-keto-PGF1a in vehicle-injected (Ctrl), mono-
crotaline-injected (MCT) and monocrotaline-injected bosentan-
treated rats (MCT BOS) given vehicle (black bars) or tezosentan
(TEZO, white bars). Gene expression was normalized for b-actin
and is presented in an arbitrary unit (AU), set as the average of Ctrl
Vehicle. *P \ 0.05 versus Ctrl, P \ 0.05 versus MCT, and
P \ 0.05 versus vehicle; n = 7 per group
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bosentan. Nevertheless, though tezosentan further atten-
uated PH it did not additionally improve CO in MCT rats
previously treated with bosentan. Results suggest tezos-
entan may be a good replacement drug when the enteric
route of administration is not tolerated or a precise real-
time control of haemodynamics is required.
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